The CB 1 cannabinoid receptor in brain is a G-protein-coupled receptor that exists as a protein possessing seven transmembrane helices that span the membrane. The intracellular surface is able to interact with G-proteins of the G i/o family to regulate effector proteins, including adenylate cyclase, Ca 2؉ channels, and K ؉ channels, and to stimulate the mitogen-activated protein kinase pathway. The CB 1 cannabinoid receptor recognizes three classes of agonist ligands: cannabinoid, eicosanoid, and aminoalkylindole. These agonist subtypes may interact with the CB 1 cannabinoid receptor by some common points of association, yet may have subtle differences in the way that they interact with the receptor protein. This may be evident in the allosteric regulation by monovalent cations and individual agonists. The juxtamembrane region of the C-terminal is able to activate G-proteins. It is proposed that conformational changes in the receptor induced by agonist ligands may alter the conformation or exposure of the juxtamembrane C-terminal region extending from helix VII.
THE CB 1 CANNABINOID RECEPTOR IN THE BRAIN
Central nervous system (CNS) responses to ⌬ 9 -tetrahydrocannabinol (⌬ 9 -THC) in Cannabis sativa and synthetic cannabimimetic drugs include the therapeutically beneficial effects of analgesia, attenuation of the nausea and vomiting in cancer chemotherapy, appetite stimulation in wasting syndromes, and reduction of intestinal motility. Untoward side effects accompanying these therapeutic responses include alterations in cognition and memory, dysphoria/euphoria, and sedation (see Abood & Martin, 1992; Dewey, 1986; Mechoulam, 1986; Hollister, 1986, for review) . The CNS responses to cannabimimetic compounds are mediated by the CB 1 cannabinoid receptor, which is a member of the family of G-protein-coupled receptors (GPCRs). CB 1 cannabinoid receptors transduce signals in response to multiple chemical classes of cannabimimetic agonists (Fig. 1 ). These include: (1) ⌬ 9 -THC-like synthetic bicyclic and tricyclic cannabinoid analogs, typified by desacetyllevonantradol (DALN), CP55940, CP55244, and HU210; (2) aminoalkylindole analogs, typified by WIN55212-2; and (3) eicosanoid cannabimimetic compounds, typified by arachidonyl ethanolamide (anandamide) and 2-arachidonyl glycerol (see DiMarzo & Fontana, 1995; Howlett et al., 1995; Pertwee, 1997 : Sheskin et al., 1997 . CB 1 cannabinoid receptors are coupled to signal transduction pathways that inhibit adenylate cyclase activity, regulate N-type Ca 2ϩ channels and G-proteinregulated inwardly rectifying K ϩ channels (reviewed in Howlett, 1995), and initiate mitogen-activated protein kinase (MAPK) and immediate early gene signaling pathway(s) (Bouaboula et al., 1995a, b) . Pertussis toxin treatment, which depletes functional G i/o proteins, has been shown to preclude cannabimimetic inhibition of cyclic AMP production in N18TG2 cells and membranes (Howlett et al., 1986) and cerebellar granule cells (Pacheco et al., 1993) , regulation of ion channels in cultured cells (Mackie & Hille, 1992) , and krox expression in glial cells (Bouaboula et al., 1995a) . Thus, it would appear that the G i/o family of G-proteins transduces the cellular responses to cannabimimetic agonists that have thus far been identified. Several reviews have described mechanisms of the receptor-mediated G-protein activation cycle (Gudermann et al., 1995; Hildebrandt, 1997; Sprang, 1997) , and these mechanisms would apply for the CB 1 cannabinoid receptor. G-protein activation requires interaction with an activated GPCR for release of GDP, binding of GTP to the ␣ subunit, and dissociation of the heterotrimer to an ␣ monomer and a ␤␥ dimer. Subsequent hydrolysis of bound GTP and reassembly of the heterotrimer facilitate reinitiation of the cycle. The ␣ subunit is believed to be important for receptor recognition in the initiation of the signal. The ␣ subunit also
